Holen Sie sich die Stockscreener-App
38.00
0.13%
-0.0157
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt NVO?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$38.02
Offen:
$38.39
24-Stunden-Volumen:
3.77M
Relative Volume:
0.17
Marktkapitalisierung:
$168.90B
Einnahmen:
$46.77B
Nettoeinkommen (Verlust:
$15.45B
KGV:
10.96
EPS:
3.468
Netto-Cashflow:
$4.40B
1W Leistung:
-1.58%
1M Leistung:
-23.40%
6M Leistung:
-30.80%
1J Leistung:
-49.97%
1-Tages-Spanne:
$37.94
$38.80
1-Wochen-Bereich:
$37.85
$39.88
52-Wochen-Spanne:
$35.85
$82.57
Novo Nordisk Adr Stock (NVO) Company Profile
Compare NVO vs LLY, JNJ, ABBV, AZN, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
38.01 | 168.94B | 46.77B | 15.45B | 4.40B | 3.468 |
|
LLY
Lilly Eli Co
|
991.63 | 872.68B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
243.79 | 583.29B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
222.39 | 398.49B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
190.65 | 298.53B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
154.45 | 294.33B | 54.72B | 14.02B | 15.32B | 7.1855 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Herabstufung | TD Cowen | Buy → Hold |
| 2026-03-03 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2026-03-02 | Herabstufung | Goldman | Buy → Neutral |
| 2026-02-24 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2026-02-24 | Herabstufung | Kepler | Buy → Hold |
| 2026-02-23 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2026-02-12 | Hochstufung | Jefferies | Underperform → Hold |
| 2026-01-27 | Eingeleitet | Citigroup | Neutral |
| 2025-12-08 | Herabstufung | Argus | Buy → Hold |
| 2025-10-27 | Fortgesetzt | Jefferies | Underperform |
| 2025-10-01 | Hochstufung | HSBC Securities | Hold → Buy |
| 2025-09-29 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2025-09-17 | Hochstufung | Berenberg | Hold → Buy |
| 2025-09-16 | Hochstufung | Rothschild & Co Redburn | Neutral → Buy |
| 2025-09-09 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2025-08-13 | Hochstufung | BNP Paribas Exane | Underperform → Neutral |
| 2025-08-05 | Herabstufung | UBS | Buy → Neutral |
| 2025-07-31 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-07-30 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-04-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2025-03-13 | Hochstufung | Kepler | Hold → Buy |
| 2025-03-03 | Herabstufung | Stifel | Buy → Hold |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2025-01-06 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-04-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-01-16 | Fortgesetzt | UBS | Neutral |
| 2023-12-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-02 | Eingeleitet | Argus | Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2022-07-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-06-28 | Herabstufung | UBS | Neutral → Sell |
| 2022-06-27 | Hochstufung | Exane BNP Paribas | Underperform → Neutral |
| 2022-06-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-05-31 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-04-25 | Hochstufung | Cowen | Market Perform → Outperform |
| 2022-04-12 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-03-16 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-01-25 | Herabstufung | Liberum | Hold → Sell |
| 2021-12-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-12-17 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-01-20 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-07-06 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-05-11 | Herabstufung | UBS | Buy → Neutral |
| 2020-05-04 | Eingeleitet | Cowen | Market Perform |
| 2020-03-16 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-11-18 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-09-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-08-30 | Herabstufung | Jefferies | Hold → Underperform |
| 2019-06-20 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2019-06-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2019-04-29 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-29 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2018-12-11 | Fortgesetzt | Jefferies | Hold |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2017-12-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2017-12-06 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2017-12-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-25 | Herabstufung | Exane BNP Paribas | Outperform → Neutral |
| 2017-09-06 | Hochstufung | BofA/Merrill | Underperform → Neutral |
Alle ansehen
Novo Nordisk Adr Aktie (NVO) Neueste Nachrichten
Novo Holdings announces 2025 Annual Results - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/SNVO - ChartMill
Novo Nordisk A/S (NVO) Expands Manufacturing to Support Rising Global Demand for GLP-1 Drugs - Finviz
Patience Pays: Hims & Hers Surges on News of Novo Nordisk Deal - Finviz
Novo Nordisk 2026 Dividend Guide for UAE Investors - Bitget
Morgan Stanley Upgrades Novo Nordisk A/S (NVO) to Equal Weight From UnderweightHere's Why - Finviz
Novo Nordisk And Hims & Hers End Bitter Legal Feud With Surprise Weight-Loss Drug Deal: Report - Sahm
Novo Nordisk (NVO) Reports 10% Sales Growth as Obesity Care Hits DKK 82B - Finviz
Roche's Obesity Drug Shows Promise But Trails GLP-1 Giants Novo Nordisk, Eli Lilly - Sahm
GLP-1 Receptor Agonist Business Analysis Report 2026: Market to Reach $137.4 Billion by 2030 - GlobeNewswire Inc.
NVO Earnings History & Surprises | EPS & Revenue Results | NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) - ChartMill
Novo Nordisk’s New Sogroya Uses And Vivtex Deal Test Valuation Gap - Sahm
JPMorgan prices Digital Barrier Notes linked to Novo Nordisk (AMJB) with 24.25% digital return - Stock Titan
Novo Nordisk A/S (NVO) Announces FDA Approval of Three New Indications for Sogroya - Finviz
Novo Nordisk A/S - TradingView
Novo Nordisk A/S (NVO) and Vivtex Corporation Announce a Partnership - Finviz
Novo Nordisk Sales Warning Tests GLP-1 Reliance And Future Growth Story - Sahm
NVO Stock Quote Price and Forecast - CNN
NVO Price History for Novo Nordisk A/S ADR Stock - Barchart.com
Novo Nordisk's Shares Drop 16.43% on CagriSema Setback and Legal Scrutiny Trading Volume Slides to 184th - Bitget
Jim Cramer Recommends Eli Lilly over Novo Nordisk - Finviz
Novo Nordisk's 40% Fall May Be Creating A Deep-Value Moment - Finviz
European ADRs Rose In US Trading, Led By HSBC And Sequans - Finimize
Ozempic Price War - Benzinga
Novo Nordisk To Slash GLP-1 Drug Prices By Up To 50% In US Starting 2027 - Sahm
Why did NVO stock crash over 14% today? Novo Nordisk’s weight-loss drug CagriSema misses trial goal agains - The Economic Times
European ADRs Slipped To Start The Week, With Pharma Leading Moves - Finimize
Novo Nordisk: Another Disappointing Cagrisema Trial Adds Pressure to High-Dose Strategy - Morningstar
Novo Nordisk Is Losing Share, but We Still See Its Portfolio and Pipeline Supporting a Wide Moat - Morningstar
Stock Of The Day: Breakdown In Novo Nordisk? - Finviz
Pre-market Overview | Uncertainty looms over US tariff policy! All three major futures indices trend lower; popular Chinese ADRs active in pre-market trading, with PDD Holdings up over 3%; Novo-Nordisk A/S plunges 14% as its next-generation weight-loss dr - 富途牛牛
Novo Nordisk sinks 16% after weight loss drug fails to match Eli Lilly's in trial - CNBC
Does Novo Nordisk A s (b Shares) Adrhedged stock benefit from AI growthQuarterly Profit Review & AI Powered Buy/Sell Recommendations - mfd.ru
Finanzdaten der Novo Nordisk Adr-Aktie (NVO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):